SRR1320180
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.417
- TNFA_SIGNALING_VIA_NFKB+0.389
- MYOGENESIS+0.319
- INFLAMMATORY_RESPONSE+0.283
- ANGIOGENESIS+0.269
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.268
- BILE_ACID_METABOLISM+0.260
- COAGULATION+0.254
- ESTROGEN_RESPONSE_LATE+0.253
- INTERFERON_ALPHA_RESPONSE+0.220
Top 10 suppressed
- MYC_TARGETS_V1-0.515
- MYC_TARGETS_V2-0.479
- DNA_REPAIR-0.463
- E2F_TARGETS-0.401
- G2M_CHECKPOINT-0.396
- PROTEIN_SECRETION-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.372
- MITOTIC_SPINDLE-0.356
- PI3K_AKT_MTOR_SIGNALING-0.325
- OXIDATIVE_PHOSPHORYLATION-0.304
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1476571 | GTEX | — | 0.924 |
| 2 | SRR1413562 | GTEX | — | 0.921 |
| 3 | SRR817775 | GTEX | — | 0.921 |
| 4 | SRR1429641 | GTEX | — | 0.917 |
| 5 | SRR1389036 | GTEX | — | 0.916 |
| 6 | SRR1491293 | GTEX | — | 0.911 |
| 7 | SRR1459585 | GTEX | — | 0.909 |
| 8 | SRR1367128 | GTEX | — | 0.909 |
| 9 | SRR1391639 | GTEX | — | 0.908 |
| 10 | SRR1435901 | GTEX | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.417 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.389 | Inavolisib | — uncovered |
| MYOGENESIS | 0.319 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.283 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.269 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.268 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.254 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.253 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.214 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.206 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.196 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.193 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.177 | Inavolisib | — uncovered |
| APOPTOSIS | 0.176 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.155 | Inavolisib | — uncovered |
| HYPOXIA | 0.152 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.136 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.126 | Inavolisib | — uncovered |